Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ARTICLE
Year: 2022   |   Volume: 11   |   Issue: 6   |   Page: 16-20     View issue

Evaluation of Interaction of Some Quinolone Derivatives on RSK-4 Using a Theoretical Model


Marcela Rosas-Nexticapa, Lauro Figueroa-Valverde, Magdalena Alvarez-Ramirez, Maria Lopez-Ramos, Virginia Mateu-Armand, Tomas Lopez-Gutierrez
Abstract

Prostate cancer is one of the leading causes of death among men worldwide; Some data suggest that ribosomal S6 p90 kinase (RSK 1-4), which belongs to the group of highly conserved Ser/Thr kinases, has been related to an increase in prostate cancer levels. For this reason, the aim of this study was to evaluate the theoretical interaction of some quinolone derivatives (compounds 1-19) with RSK-4 using 6rv2 protein and RSK-14 inhibitor (LJH685) in a docking model. The results showed that some quinolone derivatives (12, 15, 17, and 18) could interact with the 6rv2 protein surface in a different manner than LJH685. This phenomenon could be translated as greater RSK-14 inhibition, resulting in a decrease in prostate cancer levels. Analyzing these data, these quinolone derivatives could be considered good compounds to treat prostate cancer.

Cite this article
Vancouver
Rosas-Nexticapa M, Figueroa-Valverde L, Alvarez-Ramirez M, Lopez-Ramos M, Mateu-Armand V, Lopez-Gutierrez T. Evaluation of Interaction of Some Quinolone Derivatives on RSK-4 Using a Theoretical Model. Clin Cancer Investig J. 2022;11(6):16-20. https://doi.org/10.51847/wRqL2guumm
APA
Rosas-Nexticapa, M., Figueroa-Valverde, L., Alvarez-Ramirez, M., Lopez-Ramos, M., Mateu-Armand, V., & Lopez-Gutierrez, T. (2022). Evaluation of Interaction of Some Quinolone Derivatives on RSK-4 Using a Theoretical Model. Clinical Cancer Investigation Journal, 11(6), 16-20. https://doi.org/10.51847/wRqL2guumm

Downloads: 17

Views: 28
Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice
© Clinical Cancer Investigation Journal | Published by Polaris Publication
Online since 01 December, 2011
Editorial and Ethics Policies
Creative Commons  Open Access Journal View mobile site 
ISSN: Print -2278-1668, Online - 2278-0513